Tema ETFs’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tema ETFs’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,376	Closed	-$319K	–	576
2025 Q4	$319K	Buy	+5,376	New	+$293K	0.02%	436

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tema ETFs's BMRN Position: Q1 2026 in Review

Tema ETFs sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 5,376 shares — an estimated $319K sold.

Tema ETFs first reported a position in BMRN in Q4 2025 and held it in 1 quarter. The position peaked at $319K in Q4 2025. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

Tema ETFs reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Tema ETFs sold 5,376 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $319K.
Tema ETFs first reported a position in BioMarin Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Tema ETFs's BioMarin Pharmaceuticals position peaked at $319K in Q4 2025.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Tema ETFs's 13F filing for Q1 2026, filed 15 Apr 2026.